Sanofi, who will lead the global diabetes and cardiovascular care business unit in the company's new organisational structure. "The life sciences team at Google can help us improve the patient ...

Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, marked the sixth anniversary since its ...

The National Institutes of Health-supported initiative aims to collect and share AI-ready data for global scientists to analyze for new ... goals of drawing on unbiased data and protecting the ...

my research goal today was to explore whether this stock presents a buying opportunity for those building a diversified ...

After massive market cap growth for Eli Lilly and Novo Nordisk since the start of the decade, investor enthusiasm dimmed for the two most valuable companies in the industry in the third quarter.

However, Paul Hudson, CEO of Sanofi, one of the world's leading biopharmaceutical companies, says executives may need to rein ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Spire plans to use the sale proceeds to fully pay off its outstanding debt and invest in growth opportunities.

Secom Co (JP:9735) has released an update. SECOM Co., a leader in Japan’s security services industry, continues to innovate with its ...

With numerous planned submissions underway for 2024, the new platform is setting a new standard for managing simultaneous ...

Looking forward, we continue to be optimistic about the long-term outlook of the Fund's portfolio, which trades at 12.7 times ...